The impact of reducing stavudine dose versus switching to tenofovir on plasma lipids, body composition and mitochondrial function in HIV-infected patients

Antiviral Therapy

Volumn 12, Issue 3, 2007, Pages 407-415

  Milinkovic, Ana ^a   Martinez, Esteban ^a   López, Sonia ^a   De Lazzari, Elisa ^a   Mirò, Oscar ^a   Vidal, Sergi ^a   Blanco, José L ^a   Garrabou, G ^a   Laguno, Montserrat ^a   Arnaiz, Joan A ^a   Leon, Agathe ^a   Larrousse, Maria ^a   Lonca, Montserrat ^a   Mallolas, Josep ^a   Gatell, José M ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; DIDANOSINE; LAMIVUDINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; TRIACYLGLYCEROL; VIRUS RNA;

ADULT; ARTICLE; BODY COMPOSITION; BODY FAT; CD4+ T LYMPHOCYTE; CELL FUNCTION; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLACTATEMIA; LIMB; LIPID BLOOD LEVEL; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MITOCHONDRION; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TRIACYLGLYCEROL BLOOD LEVEL;

ADENINE; ADULT; ANTI-HIV AGENTS; BODY COMPOSITION; CHOLESTEROL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HIV; HIV INFECTIONS; HUMANS; LEUKOCYTES, MONONUCLEAR; LIPODYSTROPHY; MALE; MIDDLE AGED; MITOCHONDRIA; OXYGEN CONSUMPTION; PHOSPHONIC ACIDS; STAVUDINE; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 34249071420     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Nolan D, Hammond E, Martin A, et al. Mitochondrial DNA depletion and morphologic changes in adipocytes associated with nucleoside reverse transcriptase inhibitor therapy. AIDS 2003; 17:1329-1338.
2. Dube M, Parker RA, Tebas P, et al. Glucose metabolism, lipid, and body fat changes in antiretroviral-naive subjects randomized to nelfinavir or efavirenz plus dual nucleosides. AIDS 2005; 19:1807-18.
3. Gallant J, Staszewski S, Pozniak AL, et al. Long-term efficacy and safety of tenofovir disoproxil fumarate (TDF): a 144-week comparison versus stavudine (d4T) in antiretroviral-naive patients. JAMA 2004; 292:191-201.
4. Walmsley S, A Horban, R Jain, et al. Fosamprenavir/ritonavir and nelfinavir have comparable effects on body fat distribution in antiretroviral-naive patients: 48-week results from the SOLO. International Workshop on Adverse Drug Reactions and Lipodystrophy, Washington DC, USA, 25-28 October 2004. Poster L-787.
5. Shlay JC, Visnegarwala F, Bartsch G, et al. Body composition and metabolic changes in antiretroviral-naive patients randomized to didanosine and stavudine vs. abacavir and lamivudine. J Acquir Immune Defic Syndr 2005; 38:147-155.
6. Saag MS, Cahn P, Raffi F, et al. Efficacy and safety of emtricitabine vs stavudine in combination therapy in antiretroviral-naïve patients: a randomized trial. JAMA 2004; 292:180-189.
7. Domingo P, Labarga P, Palacios R, et al. Improvement of dyslipidemia in patients switching from stavudine to tenofovir: preliminary results. AIDS 2004; 18:1475-1478.
8. Moyle G, Sabin C, Cartledge J, et al. A randomized comparative study of tenofovir DF or abacavir as replacement for thymidine analogue in persons with lipoatrophy. AIDS 2006; 20:2043-2050.
9. Carr A, Workman C, Smith DE, et al. Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial. JAMA 2002; 288:207-215.
10. Martin A, Smith DE, Carr, et al. Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study. AIDS 2004; 18:1029-1036.
11. Sanchez-Conde M, Mendoza C, Jimenez-Nacher I, et al. Reductions in Stavudine dose might ameliorate mitochondrial-associated complications without compromising antiviral activity. HIV Clin Trials 2005; 6:197-202.
12. Delpierre C, Cuzin L, Alvarez M et al. Lowering stavudine dosages does not compromise anti-viral efficacy in HIV-infected patients. European AIDS Conference, Warsaw, Poland, 25-29 October 2003. Abstract 262.
13. Hanvanich M, Prasanthai V, Riengschan R, et al. Reduction of d4T dosage improves lipoatrophy without virologic failure. Antivir Ther 2003; 8:S392.
14. Wolf E, Koegl C, Hoffman C, et al. Low dose stavudine: less side effects but as effective as standard dose. Program and abstracts of the 15th International AIDS Conference, Bangkok, Thailand, 11-16 July 2004. Abstract WePeB5861.
15. Siangphoe U, Srikaew S, Waiwaravuth C, et al. Efficacy and safety of half dose compared to full dose stavudine (d4T) and zidovudine (AZT) in combination with didanosine (ddI) in Thai HIV-infected patients: 96 week results of ACTT002/ARV065 study. Program and abstracts of the 15th International AIDS Conference, Bangkok, Thailand, 11-16 July 2004. Abstract WePeB5952.
16. Saint-Marc T, Touraine JL. The effects of discontinuing stavudine therapy on clinical and metabolic abnormalities in patients suffering from lipodystrophy. AIDS 1999; 13:2188-2189.
17. Carr A, Samaras K, Thorisdotirr A, et al. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999; 353:2093-2099.
18. Carr A. for Lipodystrophy Case Definition Study Group. An objective case definition of lipodystrophy in HIV-infected adults: a case control study. Lancet 2003; 361:726-735.
19. Kanis JA, Delmas P, Buckhardt P, et al. Guidelines for diagnosis and management of osteoporosis. The European Fundation for Osteoporosis and Bone Disease. Osteoporos Int 1997; 7:390-406.
20. Bradford, M. A rapid and sensitive method for quantification of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72:248-254.
21. Cardellach F, Alonso JR, Lopez S, Casademont J, Miro O. Effect of smoking cessation on mitochondrial respiratory chain function. J Clin Toxicol 2003; 41:223-228.
22. Rustin P, Chretien D, Bourgeron T, et al. Biochemical and molecular investigations in respiratory chain deficiencies. Clin Chim Acta 1994; 228:35-51.
23. Pallotti F, Lenaz G. Isolation and subfractionation of mitochondria from animal cells and tissue culture lines. Methods Cell Biol 2001; 65:1-35.
24. Leu(UUR). Lancet 1991; 338:143-147.
25. Mirò O, Cardellach F, Barrientos A, et al. Cytochrome c oxidase assay in minute amounts of human skeletal muscle using single wavelength spectrophotometers. J Neurosci Methods 1998; 80:107-111.
26. López S, Miró O, Martínez E, et al. Mitochondrial effects of antiretroviral therapies in asymptomatic patients. Antivir Ther 2004; 9:47-55.
27. EMEA. Efficacy and safety concerns regarding the co-administration of tenofovir disoproxil fumarate (TDF, Viread) and didanosine (ddI, Videx). Public Statement 3 March, 2005 [cited 13 December 2005]. Available from: http://www.emea.eu.int/pdfs/human/press/pus/6233105en.pdf.
28. Laffeuillade A, Jolly P, Chadapaud S, et al. Evolution of lipid abnormalities in patients switched form stavudine to tenofovir-containing regiment. J Acquir Immune Defic Syndr 2003; 33:544-245.
29. Gan SK, Samaras K, Thompson CH, et al. Altered myocellular and abdominal fat partitioning predict disturbance in insulin action in HIV protease inhibitor-related lipodystrophy. Diabetes 2002; 51:3163-3169.
30. Torriani M, Thomas BJ, Barlow RB, et al. Increased intramyocellular lipid accumulation in HIV-infected women with fat redistribution. J Appl Physiol 2006; 100:609-614.
31. Martin I, Vinas O, Mampel T, et al. Effects of cold environment on mitochondrial genome expression in the rat: evidence for a tissue-specific increase in the liver, independent of changes in mitochondrial gene abundance. Biochem J 1993; 296:231-234.
32. Enriquez JA, Fernandez-Silva P, Montoya J. Autonomous regulation in mammalian mitochondrial DNA transcription. Biol Chem 1999; 380:737-747.
33. Galluzzi L, Pinti M, Troiano L, et al. Changes in mitochondrial RNA production in cells treated with nucleoside analogues. Antivir Ther 2005; 10:191-195.
34. Mallon PW, Unemori P, Sedwell R, et al. In vivo, nucleoside reverse-transcriptase inhibitors alter expression of both mitochondrial and lipid metabolism genes in the absence of depletion of mitochondrial DNA. J Infect Dis 2005; 191:1686-1696.
35. Hoy J, Gahan M, Carr A. et al. Changes in mitochondrial DNA in peripheral blood mononuclear cells from HIV-infected patients with lipoatrophy randomized to receive abacavir. J Infect Dis 2004; 190:688-692.
36. Cossarizza A. Tests for mitochondrial function and DNA: potentials and pitfalls. Curr Opin Infect Dis 2003; 16:5-10.
37. Shikuma C, Hu N, Milne C, et al. Mitochondrial DNA decrease in subcutaneous adipose tissue of HIV-infected individuals with peripheral lipodystrophy. AIDS 2001; 15:1801-1809.
38. Nolan D, Hammond E, Martin A, et al. Mitochondrial DNA depletion and morphological changes in adipocytes associated with nucleoside reverse transcriptase inhibitor therapy. AIDS 2003; 17:1329-1338.
39. Falco V, Rodriguez D, Ribera E, et al. Severe nucleoside- associated lactic acidosis in human immunodeficiency virus-infected patients: report of 12 cases and review of the literature. Clin Infect Dis 2002; 34:838-846.
40. Mussini C, Pinti M, Bugarini R, et al. Effect of treatment interruption monitored by CD4 cell count on mitochondrial DNA content in HIV-infected patients: a prospective study. AIDS 2005; 19:1627-1633.
41. Hoy J, Gahan M, Carr A, et al. Changes in mitochondrial DNA in peripheral blood mononuclear cells from HIV-infected patients with lipoatrophy randomized to receive abacavir. J Infect Dis 2004; 190: 688-692.
42. Cherry CL, Lal L, Thomson K, et al. Increased adipocyte apoptosis in lipoatrophy improves within 48 weeks of switching patients from stavudine to abacavir or zidovudine. J Acquir Immune Defic Syndr. 2005; 38:263-267.
43. Yarchoan R, Klecker RW, Weinhold KJ, et al. Administration of 3′-azido-3′-deoxythymidine, an inhibitor of HTLV-III/LAV replication, to patients with AIDS or AIDS-related complex. Lancet 1986; 1:575-580.
44. Richman DD, Grimes JM, Lagakos SW. Effect of stage of disease and drug dose on zidovudine susceptibilities of isolates of human immunodeficiency virus. J Acquir Immune Defic Syndr 1990; 3:743-746.
45. Kroon ED, Ungsedhapand C, Ruxrungtham K, et al. A randomized, double-blind trial of half versus standard dose of zidovudine plus zalcitabine in Thai HIV-1-infected patients (study HIV-NAT 001). HIV Netherlands Australia Thailand Research Collaboration. AIDS 2000; 14:1349-1356.
46. Collier AC, Bozzette S, Coombs RW, et al. A pilot study of low-dose zidovudine in human immunodeficiency virus infection. N England J Med 1990; 323:1015-1021.
47. Dudley MN, Graham KK, Kaul S, et al. Pharmacokinetics of stavudine in patients with AIDS or AIDS-related complex. J Infect Dis 1992; 166:480-485.
48. Horton C, Dudley MN, Kaul S, et al. Population pharmacokinetics of stavudine (d4T) in patients with AIDS or advance AIDS-related complex. Antimicrob Agents Chemother 1995; 39:2309-2315.